Potential Novartis psoriasis blockbuster inches closer to approval

Secukinumab's likely approval will usher in a new era wherein interleukin-17 (IL-17) inhibitors compete head-to-head with tumor necrosis factor (TNF) blockers in the plague psoriasis market. 

By Nicole Gray • Oct. 16, 2014

The Critical Path Initiative: 10 years later

There have been no treatment breakthroughs in Alzheimer’s disease since the launch of Namenda in 2003. But the Critical Path Initiative is making the AD research process more productive.

By Nicole Gray • Oct. 16, 2014

Explore the Trendline➔

Oncology's research boom

More than one quarter of the medcines cleared by the FDA's main review office since 2015 have been cancer drugs, a tally that reflects the advent of cancer immunotherapy as well as continued progress in matching treatment to genetics.

By BioPharma Dive staff

Pfizer nabs FDA priority review for potential breast cancer blockbuster

Combo therapy with letrozole and the new palbociclib improves progression-free survival by 50% in advanced breast cancer patients—still short of Roche's own potential blockbuster Perjeta.

By Sy Mukherjee • Oct. 13, 2014

Severe asthma drug breathes new life into AstraZeneca pipeline

Severe asthma patients treated with benralizumab experienced up to 70% fewer exacerbations.

By Nicole Gray • Oct. 10, 2014

Here come the layoffs: Targacept-AstraZeneca R&D partnership nixed

After 10 years of focused R&D on an Alzheimer’s disease drug, Targacept and AstraZenenca have called it quits.

By Nicole Gray • Oct. 10, 2014

Look out, AbbVie: Here comes Amgen's Humira biosimilar

Amgen's ABP501 is emerging as a serious biosimililar contender to Humira (adalimumab), which is slated to go off patent in 2016.

By Nicole Gray • Oct. 9, 2014

UPDATED: Chimerix plummets on news of Dallas Ebola patient's death

The patient was being treated with the company's experimental broad spectrum antiviral. But don't count Chimerix out just yet.

By Sy Mukherjee • Oct. 8, 2014

Catalyst Pharma to ramp up hiring after impressive orphan drug trial

Firdapse, the first-ever treatment for Lambert-Eaton myasthenic syndrome, has performed will in phase III trials.

By Nicole Gray • Oct. 8, 2014

BMS unexpectedly pulls application for hep C drug

Bristol-Myers Squibb is citing a "rapidly evolving" hep C treatment landscape as the reason for the decision.

By Sy Mukherjee • Oct. 7, 2014

Acacia Pharma braces for approval of potential blockbuster post-op nausea drug

Acacia is hoping that ADP421 will become a mainstay in treating post-operative nausea and vomiting, one of the most common surgical complications. 

By Nicole Gray • Oct. 7, 2014

Nobel committee announces 2014 winners in Physiology or Medicine

The prize was awarded for "discoveries of cells that constitute a positioning system in the brain."

By Nicole Gray • Oct. 6, 2014

Novartis and BMS co-testing lung cancer therapies

Novartis is testing three of its lung cancer drugs in combo with one of the most talked-about cancer immunotherapy drugs in development.

By Nicole Gray • Oct. 6, 2014

Optos to collaborate with UK government and universities

The $16-million collaboration is intended to develop cutting-edge optical imaging technology.

By Nicole Gray • Oct. 6, 2014

Lilly abandons lupus drug after late-stage trial failures

Some data were good for Lilly’s lupus drug, tabalumab, but overall the data were not strong enough to move forward.

By Nicole Gray • Oct. 3, 2014

Study: NSAID-related GI bleeding risk increases with combo therapy

It’s a bad idea to take Advil for a long period of time, and an even worse idea to take Advil with prednisone or warfarin, according to a study published in the latest issue of Gastroenterology.

By Nicole Gray • Oct. 3, 2014

EMA expands clinical data access to researchers and public

The European Medicines Agency has made the data available to the public with very few restrictions.

By Nicole Gray • Oct. 3, 2014

Pfizer, Kyowa Hakko Kirin partner on immuno-oncology study

The immuno-oncology revolution continues as Pfizer and Kyowa—a leading Japanese biopharma company—work together to develop solid tumor treatments.

By Nicole Gray • Oct. 2, 2014

Tekmira stock opens big on news of first US Ebola case

As the CDC announced the first locally diagnosed case of Ebola in a Texas hospital, investors rushed to Tekmira and its experimental TKM-Ebola.

By Sy Mukherjee • Oct. 1, 2014

Roche's Perjeta 'unprecedented' in extending breast cancer patients' lives

"Phenomenal," "unprecedented," and "practice-changing" are just a few of the superlatives being heaped on this treatment for aggressive, metastatic breast cancer.

By Sy Mukherjee • Sept. 29, 2014

Shareholders bullish on Nicox after phase III glaucoma trial

Vesneo (latanoprostene bunod), licensed to Valeant/Bausch & Lomb by Nicox, has been capturing the ophthalmology community's attention.

By Nicole Gray • Sept. 29, 2014

US doc treated with Tekmira Ebola drug declared virus free

Dr. Richard Sacra is the third American Ebola patient to be discharged and the first to be released after treatment with TKM-Ebola.

By Sy Mukherjee • Sept. 25, 2014

FDA to review Otsuka and Lundbeck's potential schizophrenia game changer

If approved, brexpiprazole is expected to succeed Otsuka's popular antipsychotic Abilify.

By Sy Mukherjee • Sept. 25, 2014

How the NIH is trying to get more women to participate in clinical trials

Male cells are disproportionately used in the preclinical setting, even though male and female cells react differently to both diseases and treatment.

By Nicole Gray • Sept. 24, 2014

UPDATED: Tekmira tempers expectations as regulators clear Ebola drug for emergency use

Patients in the U.S. and Canada will have access to TKM-Ebola, while a charitable organization is issuing grants to expedite clinical trials of the drug and two other Ebola treatments.

By Sy Mukherjee • Sept. 23, 2014

Study: Just one dose of antidepressant changes brain connectivity

The research finds that one dose of an SSRI increases connectivity in the cerebellum and the thalamus.

By Nicole Gray • Sept. 22, 2014